KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $1.4 billion.

  • Supernus Pharmaceuticals' Liabilities and Shareholders Equity rose 573.87% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 billion, marking a year-over-year increase of 529.03%. This contributed to the annual value of $1.4 billion for FY2024, which is 707.54% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Liabilities and Shareholders Equity of $1.4 billion as of Q3 2025, which was up 573.87% from $1.4 billion recorded in Q2 2025.
  • Supernus Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $1.8 billion during Q1 2023, with a 5-year trough of $1.3 billion in Q4 2023.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $1.4 billion (2025), whereas its average is $1.5 billion.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Liabilities and Shareholders Equity surged by 2669.01% in 2021, and later plummeted by 2721.93% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $1.7 billion in 2021, then grew by 0.79% to $1.7 billion in 2022, then decreased by 24.95% to $1.3 billion in 2023, then increased by 7.08% to $1.4 billion in 2024, then rose by 3.78% to $1.4 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.4 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.3 billion for Q1 2025.